A metabolic-activity biomarker is not a concentration test for midazolam or a measure of impairment.
What the supplied source reports
The small healthy-volunteer study compared a urinary deoxycholic-acid metabolite ratio with oral and intravenous midazolam as CYP3A probes. Itraconazole reduced the endogenous ratio, and changes correlated with the comparator measure. The reported urinary biomarker response had a time course of several days; alprazolam did not show the same inhibition pattern.
Limits of the evidence
The study used small parallel groups of healthy men and specific inhibitor regimens. Correlation was incomplete. An endogenous ratio can reflect enzyme activity over time without determining how much benzodiazepine a person took or whether the drug impaired function.
Implications for forensic interpretation
For expert interpretation, identify the analyte and the biological question it answers. A CYP3A marker may inform drug-interaction research but cannot replace drug-specific quantitative toxicology. The several-day biomarker response also differs from the minute-to-hour clinical questions often posed after sedation or an alleged impaired-driving event.
Source and related reading
Source reviewed: Evaluation of 1 Hydroxylation of Deoxycholic Acid as a Non Invasive Urinary Biomarker of CYP3A Activ (PMC8224742). Forensic applications above are interpretive analysis of the supplied publication.
Related reading: Addiction-Service Staff Confidence Did Not Validate Intoxication Detection.
Leave a Reply